A number of different intravenous iron agents are commercially available with a low toxicity profile.
Furthermore, also the carbohydrate part of the iron agents could interfere with FGF23 synthesis and degradation [ 11], and as such, apparently contradictory results could be due to the use of different iron agents.
At the 10 and 25 μg/mL dose, SFG decreased the CD4+ population more than the other IV iron agents (p < 0.05).
PBMCs from healthy volunteers were stimulated with IV iron agents SFG, IS, and ID for 72 hours at concentrations of 10, 25, and 100 μg/mL.
There are also other concerns about currently available IV iron agents, including the potential for immunogenic reaction, dose limitations and the requirement of a test dose, and the desired rate of repletion [ 6- 8].
The cells were treated for 2, 4, 8 and 24 hours with 100 μg/mL concentrations of IV iron agents Iron Dextran (ID) (INFeD®, Watson Pharma, Inc, Morristown, NJ), Iron Sucrose (IS) (Venofer®, American Regent, Shirley, NY) and Sodium Ferric Gluconate (SFG) (Ferrlecit®, Watson Pharma, Inc, Morristown, NJ).
This work aims to evaluate the applicability of EDDS (ethylenediamine-N,N′-disuccinic acid) as an iron chelating agent for photo-Fenton treatment of municipal wastewater spiked with organic contaminants at near-neutral pH.
In particular, the iron chelating agent deferoxamine could provide complete protection against mycolactone mediated cytotoxicity.
The mechanism is suggested to involve ROS and can be inhibited by the iron chelating agent deferoxamine.
To control for the effects of N- 3-oxohexanoyl -homoserine lactoN- 3-oxohexanoyl -homoserinetiN- 3-oxohexanoyl -homoserine3-oxohexaN- 3-oxohexanoyl -homoserine added to alactonernasants and reference readings potentialquantironion.
